Pincus Capital Management LP Acquires Shares of 5,766 Thermo Fisher Scientific Inc. $TMO

Key Points

• Pincus Capital Management disclosed a new stake in Thermo Fisher Scientific, buying 5,766 shares valued at about $3.34 million, making TMO its 11th-largest holding and about 2.2% of its portfolio.
• Thermo Fisher reported better-than-expected quarterly results, with earnings of $5.44 per share versus $5.25 expected and revenue of $11.01 billion, up 6.2% year over year. The company also issued FY2026 EPS guidance of $24.64 to $25.12.
• The company announced a quarterly dividend of $0.47 per share, payable July 15, while analysts currently hold a Moderate Buy consensus with an average target price of $616.10.

Pincus Capital Management LP acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 5,766 shares of the medical research company's stock, valued at approximately $3,341,000. Thermo Fisher Scientific makes up about 2.2% of Pincus Capital Management LP's portfolio, making the stock its 11th largest holding.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Assetmark Inc. raised its holdings in shares of Thermo Fisher Scientific by 22.9% during the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company's stock worth $21,819,000 after buying an additional 7,023 shares in the last quarter. Cornerstone Investment Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth $41,393,000. Mackenzie Financial Corp raised its holdings in shares of Thermo Fisher Scientific by 29.4% during the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company's stock worth $134,130,000 after buying an additional 62,790 shares in the last quarter. NEOS Investment Management LLC raised its holdings in shares of Thermo Fisher Scientific by 28.6% during the 3rd quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company's stock worth $24,913,000 after buying an additional 11,415 shares in the last quarter. Finally, Factory Mutual Insurance Co. raised its holdings in shares of Thermo Fisher Scientific by 2.6% during the 3rd quarter. Factory Mutual Insurance Co. now owns 98,935 shares of the medical research company's stock worth $47,985,000 after buying an additional 2,500 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the company's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Up 0.1%

Shares of Thermo Fisher Scientific stock opened at $493.18 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The stock's 50-day moving average is $480.40 and its 200 day moving average is $533.68. The firm has a market cap of $183.27 billion, a price-to-earnings ratio of 27.11, a PEG ratio of 2.18 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same quarter in the prior year, the company earned $5.15 EPS. The firm's revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is presently 10.34%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TMO shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Wells Fargo & Company lowered their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a report on Friday, May 8th. Jefferies Financial Group raised Thermo Fisher Scientific to a "strong-buy" rating in a report on Friday, April 24th. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a report on Friday, April 24th. Finally, Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $616.10.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.